MarginsXMarginsX
Home › Markets › Health Care › STRO

Sutro Biopharma Inc. (STRO)

STRO trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$9.32
-5.09% on the day
Market cap
$154.7M
Micro cap
Revenue · 2025
$102.5M
+65.2% on 2024
Net income · 2025
-$191.1M
-186.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1382101/000119312526119873/0001193125-26-119873-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerSTRO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2018
SEC CIK0001382101
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDELAWARE

Financials · 2025

LineValue
Revenue$102.5M
Net income-$191.1M
Operating income-$158.4M
Net margin-186.5%
Operating margin-154.5%
Revenue growth+65.2%
Cash$58.1M
Total assets$173.8M
P/E (computed)Net income was not positive
P/S (computed)1.5×

Warning signs

Cash runway
4.3 months
$46.9M cash at September 30, 2026
Share count, 1 year
+95.0%
2025-10-31 to 2026-11-06 · +172.4% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
$90K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$46.9M cash; operating cash flow -$32.4M a quarter.Report 2026-09-30
Shares outstanding16,601,411 (2026-11-06); 85,135,290 a year earlier; 60,953,204 three years earlier. 1y figure adjusted for split (1-for-10 overall); 3y figure adjusted for split (1-for-10 overall).Cover page 2026-11-06
Reverse splits, 3 years1; latest 1-for-10 on 2025-12-03Source 2025-12-03
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-02-10
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Mateo, California, United StatesPCAOB Form AP 2026-04-02
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $90K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$9.1M-$31.5M-$22.5M$46.9MNo debt tags$45.1M10-Q 2026-11-12
Q2 2026
2026-06-30
$9.8M-$38.5M-$38.3M$54.3MNo debt tags$45.7M10-Q 2026-08-12
Q1 2026
2026-03-31
$14.5M-$38.5M-$42.3M$73.7MNo debt tags$99.6M10-Q 2026-05-14
Q4 2025
2025-12-31
$11.6M-$46.8M-$26.4M$58.1MNo debt tags$102.5M10-K 2026-03-23
Q3 2025
2025-09-30
$9.7M-$56.9M-$38.2M$65.9MNo debt tags$105.6M10-Q 2026-11-12
Q2 2025
2025-06-30
$63.7M-$11.5M-$44.7M$64.0MNo debt tags$104.5M10-Q 2026-08-12
Q1 2025
2025-03-31
$17.4M-$76.0M-$67.9M$106.2MNo debt tags$66.4M10-Q 2026-05-14
Q4 2024
2024-12-31
$14.8M-$72.4M-$71.7M$190.3MNo debt tags$62.0M10-K 2026-03-23

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-04-01
Latest annual report10-K2026-03-23
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-04-22

Source: SEC EDGAR submissions feed, 628 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.1%
1 month-10.8%
3 months-53.9%
Year to date-15.1%
1 year+5.6%
From 52-week high-76.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
IPHAInnate Pharma S.A. ADS$1.41-1.06%$156.9M
IVVDInvivyd Inc.$0.5377-7.63%$158.5M
HUMAHumacyte Inc.$0.5403-3.24%$150.1M
TARAProtara Therapeutics Inc.$2.38-5.93%$146.5M
FATEFate Therapeutics Inc.$1.14-10.94%$138.6M
PALIPalisade Bio Inc.$1.03-8.04%$184.7M
ENGNenGene Therapeutics Inc.$1.89-21.58%$126.7M
CRDLCardiol Therapeutics Inc. Class A Common Shares$0.9798-2.02%$125.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier